%0 Journal Article
%T Ipilimumab-Induced Enteritis without Colitis: A New Challenge
%A Marcus Messmer
%A Mark Yarchoan
%A Matthias Holdhoff
%A Nikhilesh Mazumder
%A Reezwana Chowdhury
%A Sunita Upreti
%A Yaman Tarabishy
%J Archive of "Case Reports in Oncology".
%D 2016
%R 10.1159/000452403
%X Ipilimumab is an immune checkpoint inhibitor targeting cytotoxic T-lymphocyte associated antigen 4 (CTLA4), approved to treat metastatic melanoma. It was the first therapy shown to prolong survival in a large, randomized clinical trial. However, immune-related adverse events are common and can be severe. Enterocolitis is a common adverse event with ipilimumab, but enteritis without colitis has not been previously described
%K Ipilimumab
%K CTLA4 inhibitor
%K Enteritis
%K Colitis
%K Immunotherapy
%K Melanoma
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5126596/